Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma
oleh: Jonathan G. Pol, Manuela Lizarralde-Guerrero, Andrea Checcoli, Guido Kroemer
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2024-12-01 |
Deskripsi
Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood–brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.